Targeting this pathway has been demonstrated to impair androgen-stimulated tumor cell growth, suggesting that targeting this signaling pathway could be a potential therapeutic approach to treat ER-/HER2+ breast cancers [55]. This evidence concerns the gene ESR1 and breast cancer.